Regional Frequency Analysis of Extremes Precipitation Using L-Moments and Partial L-Moments

Extremes precipitation may cause a series of social, environmental, and ecological problems. Estimation of frequency of extreme precipitations and its magnitude is vital for making decisions about hydraulic structures such as dams, spillways, and dikes. In this study, we focus on regional frequency analysis of extreme precipitation based on monthly precipitation records (1999–2012) at 17 stations of Northern areas and Khyber Pakhtunkhwa, Pakistan. We develop regional frequency methods based on L-moment and partial L-moments (L- and PL-moments). The L- and PL-moments are derived for generalized extreme value (GEV), generalized logistic (GLO), generalized normal (GNO), and generalized Pareto (GPA) distributions. The Z-statistics and L- and PL-moments ratio diagrams of GNO, GEV, and GPA distributions were identified to represent the statistical properties of extreme precipitation in Northern areas and Khyber Pakhtunkhwa, Pakistan. We also perform a Monte Carlo simulation study to examine the sampling properties of L- and PL-moments. The results show that PL-moments perform better than L-moments for estimating large return period events

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Ganoderma multistipitatum sp. nov. from Chir pine tree (Pinus roxburghii Sarg.) in Pakistan

Background: Ganoderma species are in state of flux in Pakistan as well as in the world. The diversity of this wood-inhabiting basidiomycete in Pakistan is still poorly known. A few species have been introduced from the country; even the country is rich with many Ganoderma species, which still need identification. Methods: Ganoderma multistipitatum sp. nov. is described from Lahore, Punjab Pakistan by using the morpho-anatomical (via naked eye and compound microscope) characters and molecular data from the ITS regions of DNA. The specimens used in this study were collected from the Botanical Garden of Government College University Lahore. The G. multistipitatum sp. nov. is, to date, only known from Lahore on Chir pine tree. Results: Morphologically, this species is characterized by laccate orange, brown basidiomata, maroon, brown multi stipitate, and anatomically by ellipsoid basidiospores (10.24–11.2 × 5.3–5.4 µm) and trimitic hyphal system. The G. multistipitatum sp. nov. is 21st species from the genus Ganoderma known from Pakistan. This new species is also described with photographs, line drawings and compared with nearby taxa of the phylogenetic tree constructed by software MEGA10. This species resembled with typical G. lucidum, but the ITS DNA sequences of this species were much far away from G. multistipitatum sp. nov. ones. Conclusion: The phylogeny based on ITS sequences supported this as a new distinct species, which finally compared with closely matrixed G. multipileum and related allies. The aim of this study was to introduce the new species from genus Ganoderma, which is a major contribution in biodiversity of the world

Characterizing stomatal attributes and photosynthetic induction in relation to biochemical changes in Coriandrum sativum L. by foliar-applied zinc oxide nanoparticles under drought conditions

Abiotic stress, particularly drought, will remain an alarming challenge for sustainable agriculture. New approaches have been opted, such as nanoparticles (NPs), to reduce the negative impact of drought stress and lessen the use of synthetic fertilizers and pesticides that are an inevitable problem these days. The application of zinc oxide nanoparticles (ZnO NPs) has been recognized as an effective strategy to enhance plant growth and crop production during abiotic stress. The aim of the current study was to investigate the role of ZnO NPs in drought stress management of drought-susceptible Coriandrum sativum L. (C. sativum) in two consecutive seasons. Drought regimes (moderate drought regime—MDR and intensive drought regime—IDR) were developed based on replenishment method with respect to 50% field capacity of fully irrigated (control) plants. The results showed that foliar application of 100 ppm ZnO NPs improved the net photosynthesis (Pn), stomatal conductance (C), and transpiration rate (E) and boosted up the photosynthetic capacity associated with photosynthetic active radiation in MDR. Similarly, 48% to 30% improvement of chlorophyll b content was observed in MDR and onefold to 41% in IDR during both seasons in ZnO NP-supplemented plants. The amount of abscisic acid in leaves showed a decreasing trend in MDR and IDR in the first season (40% and 30%) and the second season (49% and 33%) compared with untreated ZnO NP plants. The ZnO NP-treated plants showed an increment in total soluble sugars, total phenolic content, and total flavonoid content in both drought regimes, whereas the abaxial surface showed high stomatal density and stomatal index than the adaxial surface in foliar-supplied NP plants. Furthermore, ZnO NPs improve the magnitude of stomata ultrastructures like stomatal length, stomatal width, and pore length for better adaptation against drought. Principal component analysis revealed the efficacy of ZnO NPs in inducing drought tolerance in moderate and intensive stress regimes. These results suggest that 100 ppm ZnO NPs can be used to ameliorate drought tolerance in C. sativum plants

Influence of Zinc Oxide Nanoparticles to Regulate the Antioxidants Enzymes, Some Osmolytes and Agronomic Attributes in Coriandrum sativum L. Grown under Water Stress

Climatic variations adversely affect the limited water resources of earth which leads to water stress and influences agricultural production worldwide. Therefore, a novel approach has been introduced to improve the tolerance against water stress in herbaceous nature medicinal plants such as Coriandrum sativum by the usage of nanotechnology (foliar applied nanoparticles of ZnOx) coupled with the application of water deficit irrigation. This is an alternative water saving strategy that proved to be efficient to mitigate the Coriandrum sativum tolerance against water stress regimes for sustainable yield production through the activation of antioxidant system. Thus, the phenomena of green synthesis have been deployed for the formation of Zinc oxide nanoparticles (ZnOx NPs) from the leaf extract of Camellia sinensis L. and zinc acetate dihydrate was used as precursor. Different techniques have been used for the thorough study and confirmation of ZnOx NPs such as UV-vis spectroscopy (UV-vis) X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), Scanning electron microscopy (SEM) and Elemental dispersive spectroscopy (EDS). The prepared ZnOx NPs exhibit hexagonal wurtzite crystal nature has an average size of 37 nm with high purity. These ZnOx NPs have been further studied for their role in amelioration of water stress tolerance in Coriandrum sativum in a pot experiment. Two levels of water stress regimes were employed, IR75 (moderate) and IR50 (Intense) to evaluate the behavior of plant compared to full irrigation (FI). Results showed that under water stress regimes, the 100 ppm of prepared NPs stimulate the antioxidant system by increasing the activity of catalases (CAT), super oxidases (SOD) and ascorbate peroxidase (APX) enzymes and found the maximum at IR50, while the concentration of malondialdehyde (MDA) decreased due to increase in activity of antioxidative enzymes. Furthermore, chlorophyll content and amount of proline also enhanced by the foliar application of prepared ZnOx NPs under moderate water stress (IR75). The results suggested that all the investigated agronomic attributes significantly increased, including plant biomass and economic yield (EY), compared to non-treated ZnOx NPs plants, except for the number of primary branches and LAI. Further, the 100 ppm of prepared ZnOx NPs have great potential to improve water stress tolerance in Coriandrum sativum by improving the antioxidant enzymes activity that enhance agronomic attributes for high crop productivity that require further research at transcriptomic and genomic level

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases : subgroup analyses of the RESTART randomised, open-label trial

Background: Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy. Methods: RESTART was a prospective, randomised, open-label, blinded-endpoint, parallel-group trial at 122 hospitals in the UK that assessed whether starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. For this prespecified subgroup analysis, consultant neuroradiologists masked to treatment allocation reviewed brain CT or MRI scans performed before randomisation to confirm participant eligibility and rate features of the intracerebral haemorrhage and surrounding brain. We followed participants for primary (recurrent symptomatic intracerebral haemorrhage) and secondary (ischaemic stroke) outcomes for up to 5 years (reported elsewhere). For this report, we analysed eligible participants with intracerebral haemorrhage according to their treatment allocation in primary subgroup analyses of cerebral microbleeds on MRI and in exploratory subgroup analyses of other features on CT or MRI. The trial is registered with the ISRCTN registry, number ISRCTN71907627. Findings: Between May 22, 2013, and May 31, 2018, 537 participants were enrolled, of whom 525 (98%) had intracerebral haemorrhage: 507 (97%) were diagnosed on CT (252 assigned to start antiplatelet therapy and 255 assigned to avoid antiplatelet therapy, of whom one withdrew and was not analysed) and 254 (48%) underwent the required brain MRI protocol (122 in the start antiplatelet therapy group and 132 in the avoid antiplatelet therapy group). There were no clinically or statistically significant hazards of antiplatelet therapy on recurrent intracerebral haemorrhage in primary subgroup analyses of cerebral microbleed presence (2 or more) versus absence (0 or 1) (adjusted hazard ratio [HR] 0·30 [95% CI 0·08–1·13] vs 0·77 [0·13–4·61]; pinteraction=0·41), cerebral microbleed number 0–1 versus 2–4 versus 5 or more (HR 0·77 [0·13–4·62] vs 0·32 [0·03–3·66] vs 0·33 [0·07–1·60]; pinteraction=0·75), or cerebral microbleed strictly lobar versus other location (HR 0·52 [0·004–6·79] vs 0·37 [0·09–1·28]; pinteraction=0·85). There was no evidence of heterogeneity in the effects of antiplatelet therapy in any exploratory subgroup analyses (all pinteraction>0·05). Interpretation: Our findings exclude all but a very modest harmful effect of antiplatelet therapy on recurrent intracerebral haemorrhage in the presence of cerebral microbleeds. Further randomised trials are needed to replicate these findings and investigate them with greater precision. Funding: British Heart Foundation